GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline (GSK) is conducting a Phase 1 clinical study titled A Two-part Phase 1 Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3862995B Following Single Ascending Doses in Healthy Participants and Repeat Doses in Participants With Chronic Obstructive Pulmonary Disease. The study aims to evaluate the safety and tolerability of the drug GSK3862995B in both healthy individuals and those with Chronic Obstructive Pulmonary Disease (COPD).
The intervention involves administering GSK3862995B, a drug intended to assess safety and tolerability, in single doses to healthy participants and repeat doses to COPD patients. The study also includes a placebo group for comparison.
This interventional study is randomized and double-blind, meaning both participants and investigators are unaware of who receives the drug or placebo. It follows a sequential intervention model and primarily aims to assess treatment effects.
The study began on November 27, 2023, with an estimated completion date not yet specified. The last update was submitted on July 16, 2025, indicating ongoing progress.
For investors, this study could impact GSK’s stock performance by potentially enhancing its portfolio with a new treatment option for COPD, a significant market. The outcome may influence investor sentiment positively if results show promise, especially in a competitive industry where advancements in COPD treatments are highly valued.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.